LCG
ADCT icon

Lynx Capital Group’s ADC Therapeutics ADCT Stock Holding History

Lynx Capital Group’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-15,000
Closed -$67.3K – 79
2024
Q1 		$67.3K Hold
15,000
– – 0.05% 79
2023
Q4 		$24.9K Buy
+15,000
New +$13.8K 0.02% 81

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Lynx Capital Group's ADCT Position: Q2 2024 in Review

Lynx Capital Group sold out of ADC Therapeutics (ADCT) in Q2 2024, closing a stake of 15,000 shares — an estimated $67.3K sold.

Lynx Capital Group first reported a position in ADCT in Q4 2023 and held it in 2 quarters. The position peaked at $67.3K in Q1 2024. 74 funds tracked by Wall St. Rank hold ADCT as of Q2 2024.

  • Lynx Capital Group reported no remaining ADC Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Lynx Capital Group sold 15,000 ADC Therapeutics shares in Q2 2024, an estimated $67.3K.
  • Lynx Capital Group first reported a position in ADC Therapeutics in Q4 2023 and held it in 2 quarters.
  • Lynx Capital Group's ADC Therapeutics position peaked at $67.3K in Q1 2024.
  • 74 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2024.

Based on Lynx Capital Group's 13F filing for Q2 2024, filed 10 Aug 2026.